(Reuters) - Genmab A/S and Seagen Inc on Monday said that the Phase III trial of Tivdak in recurrent or metastatic cervical cancer patients on or ...
- Genmab A/S and Seagen Inc on Monday said that the Phase III trial of Tivdak in recurrent or metastatic cervical cancer patients on or after front-line therapy met its primary endpoint of overall survival.
They said that an independent data monitoring committee determined that the overall survival crossed the pre-specified efficacy boundary at an interim analysis. "Demonstrating a survival benefit with the results of innovaTV 301 is a critical milestone in our efforts to ensure more adults living with advanced cervical cancer have an approved treatment option," said Seagen's Chief Medical Officer Roger Dansey.
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
SoftBank’s Arm Seeks $47 to $51 per Share in IPO, Reuters SaysSoftBank Group Corp.’s chip company Arm Ltd. will seek $47 to $51 per share from investors when it starts marketing its initial public offering next week, according to Reuters.
Read more »
North Korea says it staged 'tactical nuclear attack' drillSEOUL (Reuters) - North Korea conducted a simulated
Read more »
Two more ships pass through Black Sea corridor -Zelenskiy(Reuters) - Ukrainian President Volodymyr Zelenskiy said on Saturday that two more ships had passed through a
Read more »
North Korea stages 'tactical nuclear attack' drillBy Cynthia Kim SEOUL (Reuters) -North Korea conducted a simulated
Read more »
Two more ships pass through Black Sea corridor -Zelenskiy(Reuters) - Ukrainian President Volodymyr Zelenskiy said on Saturday that two more ships had passed through a
Read more »
Australia government to introduce bill barring 'wage theft' MondayBy Kirsty Needham SYDNEY (Reuters) - Australia's Labor government will introduce legislation to close
Read more »